Assuntos
Fator Ativador de Células B/sangue , Doenças Endêmicas , Pênfigo/sangue , Pênfigo/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Linfócitos B/metabolismo , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pênfigo/diagnóstico , Estudos Retrospectivos , Tunísia/epidemiologia , Adulto JovemAssuntos
Hepatite B/complicações , Hepatite C/complicações , Infecções por Herpesviridae/complicações , Herpesvirus Humano 8 , Pênfigo/complicações , Adulto , Anticorpos Antivirais/sangue , Feminino , Hepacivirus/imunologia , Hepatite B/sangue , Hepatite B/epidemiologia , Vírus da Hepatite B/imunologia , Hepatite C/sangue , Hepatite C/epidemiologia , Infecções por Herpesviridae/sangue , Infecções por Herpesviridae/epidemiologia , Herpesvirus Humano 8/imunologia , Humanos , Masculino , Pênfigo/sangue , Estudos SoroepidemiológicosRESUMO
Dermatomyositis (DM) is a rare inflammatory autoimmune disease for which an iatrogenic origin has been described in a few cases. The authors report a case of DM occurring after simvastatin intake. A 50-year-old male sought medical attention for a photodistributed rash and considerable muscular weakness present for 3 months. One year earlier, simvastatin had been introduced. Serum creatine kinase levels were elevated. Histological examination of a muscle biopsy was consistent with a diagnosis of DM. Investigation for neoplasia and associated autoimmune disease proved negative. All clinical and laboratory abnormalities diminished corticosteroid therapy (1 mg/kg/day). Case reports have suggested that lipid-lowering drugs, especially statins, could induce or reveal chronic muscle diseases. In statins myopathy, reduction of coenzyme Q has been discussed as a key mechanism. Our case of DM in a patient receiving simvastatin adds to the previous reported cases in the literature and highlights the potential role of statins as triggers of immune systemic diseases.